Johnson & Johnson Comments on Venezuelan Currency Devaluation

Mon Feb 25, 2013 7:45am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

NEW BRUNSWICK, N.J.,  Feb. 25, 2013  /PRNewswire/ -- Johnson & Johnson (NYSE:
JNJ) today announced that based on its preliminary assessment of the impact of
the Venezuelan government's decision to devalue its currency effective  Feb. 13,
2013, that it expects to incur a charge of approximately  $100 million  to Net
Income in the First Quarter of 2013 or approximately a  $0.04  negative impact
to earnings per share. This charge is related to the remeasurement of the local
balance sheet at the date of the devaluation and is not expected to impact
earnings per share guidance for full-year 2013 which was previously announced on
 January 22, 2013.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative ideas,
products and services to advance the health and well-being of people. Our
approximately 127,600 employees at more than 275 Johnson & Johnson operating
companies work with partners in health care to touch the lives of over a billion
people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not to
rely on these forward-looking statements. These statements are based on current
expectations of future events.  If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary materially
from the expectations and projections of Johnson & Johnson.  Risks and
uncertainties include, but are not limited to, general industry conditions and
competition; economic factors, such as interest rate and currency exchange rate
fluctuations; technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including obtaining
regulatory approvals; challenges to patents; significant adverse litigation or
government action; impact of business combinations; financial distress and
bankruptcies experienced by significant customers and suppliers; changes to
governmental laws and regulations and domestic and foreign health care reforms;
trends toward health care cost containment; increased scrutiny of the health
care industry by government agencies; changes in behavior and spending patterns
of purchasers of health care products and services; financial instability of
international economies and sovereign risk; disruptions due to natural
disasters; manufacturing difficulties or delays; complex global supply chains
with increasing regulatory requirements; and product efficacy or safety concerns
resulting in product recalls or regulatory action. A further list and
description of these risks, uncertainties and other factors can be found in
Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year
ended  December 30, 2012.  Copies of this Form 10-K, as well as subsequent
filings, are available online at, on
request from Johnson & Johnson. Johnson & Johnson does not undertake to update
any forward-looking statements as a result of new information or future events
or developments.)  

SOURCE  Johnson & Johnson

Press: Carol Goodrich, +1-732-524-6678, +1-973-615-4057 (M), or Al Wasilewski,
+1-732-524-1130, +1-732-447-5918 (M), or Investor Contacts: Louise Mehrotra,
+1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, or Lesley Fishman,
+1-732-524-3922, or Ellen Sipos, +1-732-524-3709

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.